Adial Pharmaceuticals ADIL 深 沪
已收盘 12-19 16:00:00 美东时间
0.248
-0.014
-5.27%
华盛通- 最 高0.3287
- 今 开0.26
- 成交量 50.36万股
- 最 低 0.2405
- 昨 收 0.2618
- 总市值 589.97万
- 52周最高 1.30
- 市盈率 静 --
- 换手率 2.12%
- 52周最低 0.22
- 委 比 96.08%
- 总股本 2378.90万
- 历史最高 9.44
- 量 比 1.43
- 振 幅 33.69%
- 历史最低 0.08
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
Adial Pharmaceuticals announced a public offering of 11.1 million shares of common stock and accompanying Series D and E warrants, raising approximately $3.6 million. Series D warrants are exercisable at $0.35 per share for five years, while Series E warrants have an 18-month term. Existing Series B-1 and C-1 warrants will be amended to reduce their exercise price to $0.35 per share.
06-17 12:00
【美股盤前】伊以衝突推升石油股狂飆！SK海力士股價創20年新高！美國經濟數據即將揭曉，美股能否再創新高？
伊以衝突持續，石油股繼續受益大漲；SK海力士擬建造韓國最大AI數據中心，股價創下近20年新高；美國即將公佈多項經濟數據，美股將繼續上漲？
06-17 11:33
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
Adial Pharmaceuticals submitted the briefing package for the rescheduled End of Phase 2 meeting on July 29 with the FDA to discuss Phase 3 clinical development of AD04 for Alcohol Use Disorder.
06-16 12:00
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
Adial Pharmaceuticals collaborates with Cytel to leverage machine learning for optimizing Phase 3 trial design of AD04, targeting AUD. The partnership identifies genetic subpopulations for higher efficacy and plans to launch the trial late 2025.
06-11 12:00
